Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000844715 | SCV000059720 | pathogenic | Rare genetic deafness | 2006-10-28 | criteria provided, single submitter | clinical testing | |
Molecular Diagnostics Laboratory, |
RCV000036068 | SCV000890866 | pathogenic | Usher syndrome type 1 | 2017-02-01 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000763275 | SCV000893919 | pathogenic | Autosomal dominant nonsyndromic hearing loss 11; Autosomal recessive nonsyndromic hearing loss 2; Usher syndrome type 1 | 2018-10-31 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001238560 | SCV001411380 | pathogenic | not provided | 2023-11-17 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Arg634*) in the MYO7A gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MYO7A are known to be pathogenic (PMID: 8900236, 25404053). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with Usher syndrome (PMID: 19074810). ClinVar contains an entry for this variant (Variation ID: 43164). For these reasons, this variant has been classified as Pathogenic. |
Gene |
RCV001238560 | SCV001819796 | pathogenic | not provided | 2021-02-26 | criteria provided, single submitter | clinical testing | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 32467589, 19074810, 25575603, 18564497, 9718356, 25525159) |
Centre for Clinical Genetics and Genomic Diagnostics, |
RCV001238560 | SCV005328473 | likely pathogenic | not provided | 2024-06-19 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001272497 | SCV001454569 | pathogenic | Usher syndrome type 1B | 2020-09-16 | no assertion criteria provided | clinical testing |